ArticleUltrasound (Leeds, England)2026
Comparison of ultrasonographic (SonoVue) and radiographic (Imeron) contrast agents for intralesional application in the head and neck area: An in vitro study.
Article in Ultrasound (Leeds, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to determine the suitability and optimal concentration of an ultrasonic contrast agent (SonoVue) for intralesional application during contrast-enhanced ultrasonography (CEUS). Methods: An in vitro model simulating an existing lesion in the anatomical environment of the mandibular ascending ramus was developed. After intralesional application, different SonoVue dilutions were compared with dilutions of an iodine-containing radiographic contrast agent (Imeron300) during cone-beam computed tomography. Conclusions: SonoVue provided a significant contrast effect for distinguishing the lesion from the surrounding soft tissue at dilutions of 1/10 and 1/20. Imeron300 showed a slightly superior contrast effect, even at dilutions of 1/50 and 1/100. However, CEUS using SonoVue in low dilutions seemed suitable for intralesional application in vitro. Further in vivo studies are required to validate the current results and determine the optimal contrast-agent concentration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.